UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549


FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

FOR THE MONTH OF JANUARY 2021

COMMISSION FILE NUMBER 001-39081

BioNTech SE
(Translation of registrant’s name into English)

An der Goldgrube 12

D-55131 Mainz

Germany

+49 6131-9084-0
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20‑F or Form 40‑F: Form 20‑F ☒ Form 40‑F ☐

Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(7): ☐


DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K

 

On January 11, 2021, BioNTech SE (the “Company”) provided a presentation at the JP Morgan Healthcare Conference 2021. The presentation materials are attached hereto as Exhibit 99.1.

 

 


SIGNATURE

Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

BioNTech SE

 

 

 

 

 

 

 

By:

/s/ Dr. Sierk Poetting

 

 

Name: Dr. Sierk Poetting

 

 

Title:   Chief Financial Officer

Date: January 11, 2021


EXHIBIT INDEX

 

 

Exhibit

Description of Exhibit

 

 

99.1

Next Generation Immunotherapy January 2021.

 

 

 

 

 

 

 

BioNTech (NASDAQ:BNTX)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more BioNTech Charts.
BioNTech (NASDAQ:BNTX)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more BioNTech Charts.